The Alkaptonuria Drug Market is characterized by its "ultra-orphan" status, targeting a patient population estimated at 1 in 250,000 to 1,000,000 people worldwide. The primary goal of current pharmacotherapy is to inhibit the HGD cascade to reduce HGA levels, thereby slowing the progression of irreversible tissue damage. https://stats-and-research.hashnode.dev/north-american-cannabis-market-analyzing-state-level-policy-changes-and-their-impact-on-growth-forecast-20252032